CD8⁺ T-cell-mediated immunity against malaria: a novel heterologous prime–boost strategy

References

• Rodríguez D, González-Aseguinolaza G, Rodríguez JR et al. Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium. PLoS ONE 7(4), e34445 (2012).
   Google Scholar
• Bassat Q, Alonso PL. Defying malaria: fathoming severe Plasmodium vivax disease. Nat. Med. 17(1), 48–49 (2011).
   Google Scholar
• malERA Consultative Group on Vaccines. A research agenda for malaria eradication: vaccines. PLoS Med. 8, e1000398 (2011).
   PubMed Web of Science ®Google Scholar
• Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216(5111), 160–162 (1967).
   PubMed Web of Science ®Google Scholar
• Epstein JE, Rao S, Williams F et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J. Infect. Dis. 196(1), 145–154 (2007).
   PubMedGoogle Scholar
• Rodrigues M, Nussenzweig RS, Zavala F. The relative contribution of antibodies, CD4+ and CD8+ T cells to sporozoite-induced protection against malaria. Immunology 80(1), 1–5 (1993).
   PubMed Web of Science ®Google Scholar
• Kumar KA, Sano G, Boscardin S et al. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444(7121), 937–940 (2006).
   PubMed Web of Science ®Google Scholar
• Mauduit M, Grüner AC, Tewari R et al. A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites. PLoS ONE 4(11), e7717 (2009).
   Google Scholar
• Agnandji ST, Lell B, Soulanoudjingar SS et al.; RTS,S Clinical Trials Partnership. First results of Phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365(20), 1863–1875 (2011).
   PubMed Web of Science ®Google Scholar
• Olotu A, Lusingu J, Leach A et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect. Dis. 11(2), 102–109 (2011).
   PubMed Web of Science ®Google Scholar
• Li S, Rodrigues M, Rodríguez D et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc. Natl. Acad. Sci. USA 90(11), 5214–5218 (1993).
   PubMed Web of Science ®Google Scholar
• Rodrigues M, Li S, Murata K et al. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J. Immunol. 153(10), 4636–4648 (1994).
   PubMed Web of Science ®Google Scholar
• Schneider J, Gilbert SC, Blanchard TJ et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4(4), 397–402 (1998).
   PubMed Web of Science ®Google Scholar
• McConkey SJ, Reece WH, Moorthy VS et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9(6), 729–735 (2003).
   PubMed Web of Science ®Google Scholar
• Dunachie SJ, Walther M, Epstein JE et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect. Immun. 74(10), 5933–5942 (2006).
   PubMed Web of Science ®Google Scholar
• Bejon P, Ogada E, Mwangi T et al. Extended follow-up following a Phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS ONE 2(8), e707 (2007).
   PubMed Web of Science ®Google Scholar
• Bejon P, Andrews L, Andersen RF et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J. Infect. Dis. 191(4), 619–626 (2005).
   PubMed Web of Science ®Google Scholar
• López-Macías C, Ferat-Osorio E, Tenorio-Calvo A et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 29(44), 7826–7834 (2011).
   PubMed Web of Science ®Google Scholar
• Lori F. DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS. Expert Rev. Vaccines 10(10), 1371–1384 (2011).
   PubMed Web of Science ®Google Scholar
• Braun M, Jandus C, Maurer P et al. Virus-like particles induce robust human T-helper cell responses. Eur. J. Immunol. 42(2), 330–340 (2012).
   PubMed Web of Science ®Google Scholar